Genmab A/S (GMAB)
| Market Cap | 19.47B |
| Revenue (ttm) | 3.85B |
| Net Income (ttm) | 1.58B |
| Shares Out | 61.57M |
| EPS (ttm) | 25.10 |
| PE Ratio | 1.26 |
| Forward PE | 22.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,521,302 |
| Open | 31.58 |
| Previous Close | 31.39 |
| Day's Range | 31.32 - 31.82 |
| 52-Week Range | 17.24 - 33.65 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 40.40 (+27.41%) |
| Earnings Date | Nov 6, 2025 |
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price target is $40.4, which is an increase of 27.41% from the latest price.
News
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; December 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, ...
Artisan International Small-Mid Fund Q3 2025 Performance Review
Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest ...
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami
Media Release COPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Citi Globa...
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Con...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility
Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced thei...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The incr...
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. ...
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market...
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer,...
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript
Genmab A/S (GMAB) Q3 2025 Earnings Call November 6, 2025 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head ...
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London
Media Release COPENHAGEN, Denmark; November 5, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will par...
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneous...
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Why Is Genmab Stock Trading Lower On Monday?
On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endom...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigati...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
Company Announcement Net sales of DARZALEX ® in the third quarter of 2025 totaled USD 3,672 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Why Genmab Stock Popped on Friday
Before the market open on the last trading day of the week, two analysts tracking Genmab (GMAB 4.48%) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bu...
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Why Genmab Stock Was Marching Higher Today
One day after announcing a sizable acquisition, Denmark-based biotech Genmab (GMAB 4.67%) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the comp...
Genmab A/S (GMAB) M&A Call Transcript
Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimen...
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
Genmab will acquire Merus in an all-cash transaction worth around $8 billion.
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...